CareDx Inc (NASDAQ:CDNA) has received an average recommendation of “Buy” from the six analysts that are currently covering the firm, MarketBeat.com reports. Two equities research analysts have rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average twelve-month price objective among brokers that have issued a report on the stock in the last year is $8.88.
CDNA has been the subject of several analyst reports. ValuEngine lowered shares of CareDx from a “hold” rating to a “sell” rating in a report on Wednesday, January 10th. HC Wainwright restated a “buy” rating and set a $12.00 price target on shares of CareDx in a report on Wednesday, January 31st. Finally, Zacks Investment Research lowered shares of CareDx from a “buy” rating to a “hold” rating in a report on Thursday, January 11th.
CareDx (NASDAQ:CDNA) traded up $0.06 during trading on Wednesday, reaching $5.80. 132,619 shares of the company’s stock traded hands, compared to its average volume of 198,513. The company has a current ratio of 0.55, a quick ratio of 0.35 and a debt-to-equity ratio of -124.53. CareDx has a 52-week low of $0.76 and a 52-week high of $7.98. The company has a market cap of $164.18, a price-to-earnings ratio of -3.28 and a beta of 0.72.
CareDx Company Profile
CareDx, Inc is a molecular diagnostics company. The Company is focused on the discovery, development and commercialization of clinically differentiated diagnostic surveillance solutions for transplant patients. The Company’s commercialized testing solution, the AlloMap heart transplant molecular test (AlloMap), is a gene expression test that helps clinicians monitor and identify heart transplant recipients with stable graft function having a low probability of moderate/severe acute cellular rejection.
Receive News & Ratings for CareDx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CareDx and related companies with MarketBeat.com's FREE daily email newsletter.